Teva Surges on Robust Outlook, Allergan Deal

Tether had a strong Q2, surpassing analyst expectations with earnings per share between $1.19 and $1.22 and revenues between $4.9 and $5 billion. CEO Erez Vickerman reassured investors about the $40 billion Allagan takeover, despite some delays and adjustments. He also projected significant revenue growth by 2019. However, challenges remain, including realizing synergies, competition, and potential cultural differences in the merger.

How much in synergies does Tether expect to gain from the merger?

What challenges are associated with the merger between Tether and Allergan?